Introduction
============

Urothelial carcinoma (UC) is the most common epithelial neoplasm arising from the entire urothelium of the urinary tract including upper urinary tract descending to distal urethra. Of these anatomic locations, urinary bladder urothelial carcinoma (UBUC) remains the most common, while upper urinary tract urothelial carcinomas (UTUC) are rare, comprising only 5% to 10% of all UCs [@B1]. Our analysis assumes that both UTUC and UBUC share similarities regardless of location, but some exposures seem more specific to UTUC, such as in patients with aristolochicacid-induced nephropathies as a result of either Chinese herb toxification or Balkans endemic nephropathy, in those associated with chronic phenacetin abuse, and in Blackfoot disease prevalent on the southwest coast of Taiwan [@B2]. Although there is a greater genetic predisposition to UTUC implicating Lynch syndrome \[Hereditary non-polyposis colorectal cancer (HNPCC) syndrome\] and promotor hypermethylation, it shows widely similarity for UTUC and UBUC in the molecular biology [@B3]-[@B5]. In addition, the behavior of both diseases is identical after adjusting for tumor stage and histological grade [@B6]. This may indicate that both UTUC and UBUC involve a similar tumorigenesis pathway.

STAT5 proteins play a pivotal part in this multistep process of tumorigenesis. Research has implicated their involvement in cytokine signaling, as well as in mediating the expression of specific genes dealing with cell proliferation, apoptosis, induction of cell differentiation, and inflammation. Though STAT 5A and STAT 5B, two relevant transcription factors of the STAT5 family, are encoded by separate genes, they are 90% the same at the amino acid level [@B7]. Growing evidence suggests that the constitutive phosphorylation of these STAT5 proteins plays a key role in oncogenesis, and they have been closely connected to human cancers including a majority of leukemias and several kinds of malignancies such as breast, prostate, and head and neck cancers [@B8]-[@B11]. Nevertheless, fibroblast growth factor receptor-3 (FGFR3), a member of tyrosine kinase receptor family, is found to be implicated in the tumorigenesis of multiple cancers including UBUCs and other urothelial cancers [@B12], [@B13]. Besides, it could stimulate phosphatidylinositol 3-kinase (PI3K) and STAT, ensuing activation of the STAT pathway [@B14]. Despite this knowledge, however, the activation mechanism of STAT5 has not been systemically investigated in UC [@B15], [@B16]. This we will accomplish with our analysis of these well-known transcription factors and their place in UBUC tumor development.

By performing data mining from a published transcirptomic dataset of UBUCs (GSE32894), we have clarified colony stimulating factor 2 gene (*CSF2*, granulocyte macrophage-colony stimulating factor), as the most upregulated gene of significance for tumor development and invasiveness among those associated with positive regulation of tyrosine phosphorylation of STAT5 (GO:0042523). CSF2 is a cytokine functioning as hematologic cell growth factor that operates by stimulating stem cells to produce granulocytes and monocytes; though STAT5 can be activated by several cytokines and hormones including interleukins (IL-2, IL-3, IL-5 and IL-7), thrombopoietin, erythropoietin , growth hormone, insulin and prolactin, it is the preferred member of the STAT family activated by CSF2 [@B9], [@B10], [@B17]-[@B22]. CSF2 also activates at least three signaling pathways: the Janus kinase (JAK) 2/STAT pathway [@B19]-[@B21], the ras/mitogen-activated protein kinase (MAP kinase) pathway [@B22], and the PI3K pathway [@B23]. In this light, an examination of STAT 5 proteins on the tumorigenesis of UBUCs demands a comprehensive analysis of CSF2 transcript and protein expression. Furthermore, we also examined the associations of CSF2 transcript and protein expression with clinicopathological parameters and disease-survival in our well-estalished cohort of UC.

Materials and Methods
=====================

Analysis of published transcriptomic database
---------------------------------------------

To identify genes pivotal in pathogenesis and tumor invasiveness in UC, data mining by use of the GEO (National Center Biotechnology information, Bethesda, MD, USA) was done. One dataset, GSE32894 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32894> ) analyzing radical cystectomy tissues from 308 UBUCs by the use of v3.0 of Illumina HumanHT-12 expression beadchip, was recognized. The raw CEL files that were imported into Nexus Expression 3 software (BioDiscovery) were utilized to computerize the expression level. There was no preselection or filtering in all probe sets for the analysis. We used supervised comparative analysis and functional profiles to analyze which transcripts were differentially expressed with statistical significance, focusing on pathways associated with positive regulation of tyrosine phosphor-STAT5 (GO:0042523), based on primary tumor status (pT) and distant metastasis. Those differentially expressed between high-stage (pT2-pT4) UC with metastasis and low-stage (pTa-pT1) UC without metastasis was compared for further analysis. Genes with significantly differential expression (p\<0.001) were chosen. All enrolled 308 cases were dichotomized to high- and low-expression clusters for further survival analysis to computerize the potential valuable prognosticators of selected genes.

Patients and tumor specimens
----------------------------

After obtaining the approval of the institutional review board (IRB) of Chi Mei Medical Center (Tainan, Taiwan), all the using UC samples (IRB10302015) with the informed consents and sampling procurement were retrieved and analyzed from the hospital BioBank. For immunohistochemistry and survival analysis, we studied data on urothelial carcinoma cases from between 1996 and 2004 as previously described [@B24]-[@B26]. A total of 635 well-characterized cases were selected: 340 UTUCs and 295 UBUCs. Nephroureterectomy with resection of the bladder cuff and regional lymphadectomy were undergone in all the UTUC patients. Transurethral resection of the bladder tumor (TURBT) was performed on those who were diagnosed with superficial UBUC (pTa and pT1), with or without subsequent intravesical BCG. Patients whose tumors recurred received radical cystectomy as salvage treatment. For UBUC showing muscular invasion, radical cystectomy with bilateral pelvic lymph node dissection was done. Cisplatin-based adjuvant chemotherapy was applied to pT3 or pT4 tumor stage and/or nodal metastatic UBUC patients. Carboplatin was introduced in those with renal insufficiency. Nevertheless, there were just 29 of 106 cases with pT3 or pT4 stage and/or lymph node positive UTUC intervened by adjuvant chemotherapy. There was no application of neo-adjuvant chemotherapy to in this current cohort. The criteria evaluated for the clinicopathological features were basically the same as our previous work [@B27], [@B28]. For UTUC, mutifocality was included for evaluation and only the most invasive lesion which showed the highest pT status was used for the classification of pT status. For UBUC, multifocality was not studied, but the most invasive lesion was used for the determination of pT status similarly. Those patients with synchronous UTUC and UBUS were carefully excluded. The mean follow-up duration for UTUTC and UBUC was 44.7/30.8 months while the median interval was 38.9/23.1 months for each UCs. Histopathological diagnosis of each case was reappraised by two pathologists (I.W.C and C.F.L) on hematoxylin-eosin (H&E) sections according to the current World Health Organization/International Society of Urologic Pathology consensus classification [@B12]. The vascular invasion was defined as the presence of tumorous thrombi/emboli in the endothelium-lined vascular channel and the perineural invasion was determined by cancer cells wrapping the nerve bundles. Both were directly observed on H&E slides. Low and high mitotic activity were determined by the mitotic rate which was achieved by calculating mitotic counts per 10 high-power fields (HPFs; 400x light microscopic magnification). It is defined as low mitotic rate with a mitotic rate less than 10/10 HPFs, and high mitotic activity with a rate 10 or more. Another independent cohort using 24 fresh UBUC samples was introduced, with a high content of tumorous tissue and 6 non-tumorous urothelial samples, and was selected for determination of *CSF2* mRNA expression detected by real-time RT-PCR assay. Twelve cases fall into pTa- pT1 and the remaining 12 cases to pT2 and higher stages.

Real-time RT-PCR
----------------

The archived frozen tissue was carefully examined to obtain twenty-four UBUC cases with a high tumor percentage of more than 70%. For quantification, total RNAs from these cases were extracted for reverse-transcription. Pre-designed TaqMan probe targeting *CFS2* (hs00929873_m1, Applied Biosystems) was performed to measure the mRNA amount with the ABI StepOnePlus™ System as described in our previous studies [@B28], [@B29]. Followed by the internal control of normalization to *POLR2A* (Hs01108291_m1), the expression folds of *CSF2*was calculated to show association with normal urothelium by comparative C~t~ method.

Immunohistochemical staining CSF2 and phosphor-STAT5
----------------------------------------------------

After histopathological review for immunohistochemistry, we selected representative tissue blocks with the deepest invasiveness for each case. Tissues retrieved from paraffin-embedded sections were cut at 4-μm thickness, followed by deparaffinization with xylene, rehydration with ethanol, and the retrieval of antigen. The endogenous peroxidase was quenched by saline for 15 minutes and then incubated with primary monoclonal antibodies against CSF2 (1:100, Cat. No. ab77768, rabbit polyclonal, abcam, Cambridge, MA) and phosphor-STAT5 (pSTAT5, Tyr 694/Tyr 699) (1:50, Cat. No. sc-11761, goat polyclonal, Santa Cruz, CA) for an hour. DAKO ChemMate EnVision Kit (K5001, Carpinteria, CA, USA) was used for detecting these primary antibodies. Target cells expressing brown cytoplasmic chromogen were shown to have immunopositivity. The normal urothelium was used as the positive control, while no incubated primary antibody served as a negative control.

Assessment and scoring of CSF2 and pSTAT5
-----------------------------------------

CSF2 and pSTAT5 immunoexpression was generated by two pathologists (I.W.C & C.F.L) blinded to patients\' clinical information. A histological score (H-score) was obtained by assessing both the percentage and staining intensity of cancer cells with cytoplasmic expression of CSF2. It was calculated briefly by the use of the equation as belowe: H-score=Σ*P~i~*(*i*+1), where *i* is the intensity of stained cancer cells (ranging from 0 to 3+), and *Pi* is the percentage of positive-stained cancer cells of intensity from 0%-100%. The generated score ranged from 100-400. 0% of tumor cells with immunopositivity denoted 100 and 100% of cancer cells expressed strong immunostaining (3+) represented 400, the same scoring criteria as reported previously [@B28], [@B30], [@B31].

Statistical analysis
--------------------

SPSS v14.0 software package (SPSS Inc. Chicago, IL, USA) was performed for statistical analyses. Median H-score of CSF2 as cutoff was determined to dichotomize patients into high- and low-expression clusters. It were examined the associations of CSF2 expression status with clinicopathological variables using the chi-square test. The endpoints analyzed were DSS and MeFS which were decided since the commencement of curative surgery to the date an event developed. Those with loss of follow-up were decided primarily on the latest appointment. Survival curves were plotted by the use of Kaplan-Meier method and evaluated prognostic differences between groups by the log-rank test. For those with *p*-values less than 0.05 at the univariate level, the parameters were then joined into multivariate tests by the use of the Cox proportional hazards model. Two-sided tests was used with *p*\< 0.05 that was considered statistically significant.

Results
=======

*CSF2* as a differentially upregulated transcript of significance relating to positive regulation of tyrosine phosphorylation of STAT5 in UBUC
----------------------------------------------------------------------------------------------------------------------------------------------

From the validation dataset of 308 cases (GSE32894), we focused on nine probes covering eight transcripts implicated in the positive regulation of tyrosine phosphorylation of STAT5 (GO:0042523). Among these, there were only two probes containing two genes significant differentially expressed in increment of pT stage and metastatic events, including the upregulation of *CSF2 and IGF* (Fig. [1](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}). Nonetheless, *CSF2* stands for the most significantly implicated, with a log2 ratio of 0.4506-fold upregulation associated with incremental pT status. Interestingly, *CSF2* also shows a stepwise increment from pTa to pT1 and from pT1 to pT2-T4 lesions with log2 ratios of 0.2204 (p=0.0048) and 0.2130 (p=0.0157), respectively. These findings prompted us to justify whether the CSF2 expression was of significance in this current cohort of UCs. Moreover, we also explored the relation between CSF2 expression and STAT5 phorphorylation and its significance.

Clinicopathological findings for UTUC
-------------------------------------

The clinicopathological parameters of the UTUC cases were enclosed in Table [2](#T2){ref-type="table"}. There was no evident gender preference, with a median of 68 years at initial diagnosis (34-87 years). Sixty-two cases (18.2%) presented with multifocal diseases, 49 (14.4%) of which showed synchronously tumor involvement of the renal pelvis and ureter. There were 284 patients (83.5%) with high histological grade and 159 (46.8%) with advanced pT stage (pT2-T4). Frequent mitoses were detected in nearly half of the patients (n=167, 49.1%). 106 cases (31.2%) exhibited vascular invasion while only 19 (5.9%) had perineurial invasion. Nodal involvement was identified in 28 cases with UTUCs (8.2%).

Clinicopathological findings for UBUC
-------------------------------------

As shown in Table [2](#T2){ref-type="table"}, male sex accounted for 73.2% of UBUC patients (n=216), most of which were elder than 60 years (n=214, 72.5%). The majority of these patients (n=239, 81%) showed severe histological grade, and less than half (n=123, 41.7%) presented with advanced stage (pT2-T4). 156 cases (52.9%) were found to have high mitotic activity formerly defined as ≥ 10. Nodal metastasis was found in 29 patients (23.6%). Vascular invasion was detected in 16.6% (n=48) of patients and perineurial invasion was found only in 6.8% of patients (n=20).

*CSF2* mRNA expressing more scarcely in high tumor stage and nodal metastatic UBUC
----------------------------------------------------------------------------------

In 24 analyzed cases, *CSF2* mRNA showed lower expression and increased pT status (*P*=0.010) in UBUC and significantly differentiated early-stage UBUC from non-tumor urothelium (*P*=0.041) (Fig. [2](#F2){ref-type="fig"}).

Correlations of immunopositivity of CSF2 and pSTAT5 with clinicopathological variables in UTUC and UBUC
-------------------------------------------------------------------------------------------------------

Cytoplasmic immunoreactivity of CSF2 was expressed variably in both the UTUC and UBUC (Fig. [3](#F3){ref-type="fig"}). The median H-scores of UTUC and UBUC were 205 and 210 for each. Table [2](#T2){ref-type="table"} showing dichotomized results of low and high CSF2 expression groups, increased CFS2 expression was related significantly to high pT status (UTUC, *P*=0.011; UBUC, *P*\<0.001), nodal metastasis (UBUC, *P*=0.030), higher histological grade (UBUC, *P*=0.008), vascular (UBUC, *P*\<0.001) and perineurial (UTUC, *P*=0.002; UBUC, *P*=0.001) invasions in UC. Detailed information as summarized in Table [S1](#SM1){ref-type="supplementary-material"}, high pSTAT5 expression was associated with increment of pT (UTUC, *P*=0.004; UBUC, *P*\<0.001), nodal status (UTUC, *P*=0.049; UBUC, *P*=0.004), and the presence of vascular permeation (UTUC, *P*=0.035; UBUC, *P*=0.001). Interestingly, high CSF2 expression significantly correlated with pSTAT5 expression in both UTUC and UBUC (each *P*\<0.001), suggesting a link between CSF2 expression and STAT5 activation.

Survival analysis for UTUC
--------------------------

The median follow-up period was 38 months (ranging from 1-176 months). The clinical outcomes of UTUC patients with associated clinicopathological factors in the univariate and multivariate analyses were demonstrated in Table [3](#T3){ref-type="table"}. It demonstrated that inferior DSS was significantly inferred in histological grade (*P*=0.014), multifocality (*P*=0.026), nodal involvement (*P*\<0.001), and perineurial invasion (*P*=0.001) in multivariate comparison. MeFS showed similar findings. The pT status at presentation and vascular permeation in UTUC were only significantly implicated in inferior DSS and MeFS at the univariate analysis. Though a trend toward unfavorable clinical course, the anatomic locations of UTUCs were correlated with poor DSS at univariate analysis only.

Survival analysis for UBUC
--------------------------

All patients with available follow-up interval showed a median 23.1 months (ranging from 1 to 109 months). Notably, the increment of pT stage and mitotic rate in UBUC were significantly associated with shorter DSS (p\<0.001 and p=0.018, respectively) and MeFS (p=0.001 and p=0.030, respectively) in the multivariate comparison, as demonstrated in Table [4](#T4){ref-type="table"}. The multivariate comparison showed no further relations to morbid DSS and MeFS for those significant parameters including histological grade, vascular and perineural invasions, and lymph node involvement identified at univariate analysis.

Prognostic significance of CSF2 and pSTAT5 expression in UC
-----------------------------------------------------------

In Table [3](#T3){ref-type="table"}, cases with UTUC expressing high CSF2 cytoplasmic immunoreactivity had significantly inferior DSS (*P*=0.0001, Fig. [4](#F4){ref-type="fig"}A) and MeFS (*P*=0.0001, Fig. [4](#F4){ref-type="fig"}B) in univariate analysis. Those with UBUC were observed to show similar results (Table [4](#T4){ref-type="table"}, Fig. [4](#F4){ref-type="fig"}C, and Fig. [4](#F4){ref-type="fig"}D). Specifically in the multivariate comparison, it remained prognostically independent for overexpression of CSF2 with significantly shorter DSS and MeFS in all UCs (Table [3](#T3){ref-type="table"} and Table [4](#T4){ref-type="table"}). Increment expression of pSTAT5 was only inferred to worse DSS and MeFS for both UTUC and UBUC in univariate analysis.

Discussion
==========

Using immunohistochemistry, we have demonstrated that the overexpression of CSF2 strongly correlates with advanced disease in both UTUC and UBUC, including high tumor stage and identifiable perineural invasion. Furthermore, CSF2 was suggested to independently correlate with worse clinical outcomes, DSS and MeFS, in both UTUC and UBUC. These findings are in parallel with those observed in a variety of non-hematopoietic malignant tumors, such as lung cancers [@B32], [@B33], gliomas [@B34], and bladder cancers [@B35]-[@B37].

The cytokine CSF2 which coordinates granulopoiesis and mobilization of neutrophils to peripheral blood is secreted by fibroblasts, endothelial cells and the cells of the immune system encompassing monocytes/macrophages and activated T lymphocytes [@B17], [@B18]. To initiate the intracellular signaling pathway promoting cell survival, proliferation and differentiation, a ligand-specific subunit (GM-CSFR) heamer is required. This hexamer is composed of a ligand-specific subunit (GM-CSFRα) and a beta subunit (βc) which is shared with the IL-3 and IL-5 receptors, allowing for association with Janus kinase 2 (JAK2) [@B23], [@B38], [@B39]. CSF2-dependent phosphorylation of JAK2 and the subsequent recruitment of STAT5 have been suggestive of affecting cellular differentiation, and are required steps in promoting oncogenesis [@B10]. In the present study, both high pSTAT5 and CSF2 expression correlated with higher pT and nodal status in UTUCs and UBUCs but only CSF2 overexpression served as an inferior prognostic factor in multivariate analysis. These findings indicate that CSF2 rather than STAT predicts a poor prognosis in patients with UCs. As we know, more than 70% of papillary non-invasive UCs and 10-20% invasive UCs harbor FGFR3 mutations [@B12]-[@B14]. In addition, FGFR3 can directly or indirectly activate the STAT pathway, just like that in CSF2- triggering constitutive phosphorylation of STAT [@B14]. This may partially explain why CSF2 but not pSTAT5 is more upregulated in UCs. However, the contribution of CSF2 to cancer stem cell phenotypes is still not clear [@B40]. There is compelling evidence showing that various solid tumors secrete CSF2, including lung cancers, gliomas, bladder cancers, head and neck cancers, melanoma and skin carcinomas, and colorectal cancer [@B32]-[@B36], [@B41]-[@B44].

Of the tumors associated with the GM-CSF signaling pathway, we found contradictory results in different groups, some showing an anti-proliferative effect while others revealed the promotion of tumor growth [@B43], [@B45]-[@B47]. In the most frequent type of ectopically CSF2-secreted malignancy\--primary and metastatic pulmonary cancers\--we propose that cytokines secreted by tumor-associated endothelial cells promote angiogenesis as well as metastasis via increased expression of cell adhesion molecules [@B32], [@B33], [@B48]. Though not common, bladder cancers have also been found to have higher tumor grades associated with the concomitant expression of elevated CSF2 and GM-CSFR [@B35], [@B36]. Autocrine and paracrine growth stimulated by GM-CSFR might explain the aggressiveness of these mainly UC. [@B36]. Comparing bladder cancers to normal tissues, Sanchez-Carbayo et. al. [@B37] and Lee et. al. [@B49] have each reported microarray data indicating increased gene expression of both CSF2 and a-subunits of GM-CSFR. Our analysis, pointing to the close correlation of CSF2 overexpression in UBUCs with advanced tumor stages and poor outcomes, is consistent with Sanchez-Carbayo\'s and Lee\'s findings. Furthermore, this is the first report to date showing the overexpression of CSF2 in UTUC as well as in UBUC, thus implying that CSF2 plays a role in the progression of urothelial carcinoma.

Unlike in many other malignancies, however, ectopic secretion of CSF2 in colorectal cancers is found to display both immune-mediated and immune independent antitumor effects [@B45]. It has been observed that the immune-independent antitumor effect is dependent on the ectopic expression of GM-CSFR subunits of tumors [@B45]. Similarly, overall five-year survival is improved in patients with colorectal cancers that overexpress CSF2 and its receptor subunits. Secretion of CSF2 in melanoma and skin carcinoma has also been shown to covey antitumor effects [@B42], [@B43], [@B47]. CSF2 secretes a soluble VEGF receptor in transgenic mouse melanoma, further inactivating VEGF and exerting antiangiogenic effects [@B42]. In skin cancers, CSF2 may exhibit anti-proliferative activity via modulating VEGFR secretion and the recruitment of tumor-associated macrophages [@B43], [@B46].

Furthermore, it has been found that constitutive STAT5 signaling plays a pivotal role in the pathogenesis of vast hematological malignancies and several solid tumors [@B8]-[@B11]. Wang et al [@B50] indicated that aberrant Ras/ERK signaling results in proliferation of monocytic/granulocytic precursors, which are sufficient to induce CSF2-dependent STAT5 hypersensitivity in murine models. Furthermore, Padron et al [@B39] demonstrated 90% of chronic myelomonocytic leukemias with CSF2-dependent STAT5 hypersensitivity were enhanced by signaling mutations. Is it activation of the CSF2-mediated JAK-2/STAT-5 pathway that promotes maintaining tumor cell survival and/or proliferation or via autocrine secretion of CSF2 [@B51]? In our study, significant correlation of high expression of CSF2 with pSTAT5 expression in both UTUC and UBUC suggests a potential link between CSF2 expression and STAT5 activation. Moreover, the close correlation of CSF2 overexpression with advanced tumor stages and poor outcomes may infer an autocrine effect that plays a more important role in the maintenance of proliferation in UCs.

These findings suggest potential oncogenic properties and therapeutic implications related to CSF2 expression in UCs. Several therapeutic interventions targeting GM-CSF, such as Mavrilimumab (human anti-GM-CSFRα Ab) and MOR103 (human anti-GM-CSF mAb), have been developing by blocking cytokine-receptor interaction and receptor activation [@B52], [@B53]. Consequently, pharmaceutical inhibition of these monoclonal antibodies might be a strategy for inactivating CSF2. In addition, there are therapeutic targets at cancer treatments with pSTAT5 are proposed for a majority of hematologic malignancies and some epithelial tumors such as prostate and breast cancers, via either indirect or direct inhibition of STAT5 activity [@B54], [@B55]. Drugs aiming at indirect inhibition of the STAT5 protein signaling pathway, such as imatinib and lestaurtinib, may result in non-specific effects of increased cell toxicity, and might be better handled by direct inhibition [@B56], [@B57]. Small molecule STAT5-SH2 domain inhibitors that prevent proper dimerization have been proposed to be one of the most potent direct, non-phosphorylated inhibitors of STAT5 [@B55]. These results suggest the therapeutic potential of targeting STAT5 inhibitors as adjunct to anti-GM-CSF could be used to diminish CSF2 activity in UCs that overexpress CSF2.

Last but not least, various pro- and anti-tumorigenic roles of CSF2 are addressed in different types of solid cancers. As a general rule, recombinant G- or GM-CSFs are routinely introduced to adjust cancer therapy-related neutropenia in clinical oncology. Nonetheless, adjuvant G-/GM-CSF regimen have been correlated with iatrogenic tumor growth [@B58], [@B59]. Caution is warranted, however, and strict eligibility criteria are called for when using these recombinant cytokines in patients who require the treatment. In addition, prompt diagnosis of tumor types would aid in individualizing anticancer therapies, such as GGM-CSF-secreted vaccines for patients with melanomas and could help avoid certain adverse effects of exacerbated tumor growth in tumor cells addicted to G-/GM-CSF [@B46].

In conclusion, our date revealed for the first time that overexpression of CSF2 overexpression was implicated with advanced tumor status and more aggressive clinical courses. More importantly, it acts as a valuable prognostic indicator in both tumor development and progression of UC and may serve as a novel therapeutic target for treatment.
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![**Analysis of gene expression** from a published transcriptome in UBUC (GSE32894) focusing on pathways related to positive regulation of tyrosine phosphorylation of STAT5 (GO:0042523). It shows *CSF2* as the most significant gene that is differentially expressed with higher tumor stages. In the heatmap, different pT statuses obtained from tumor tissues are indicated on top, and upregulation and downregulation of genes are illustrated as a spectrum of brightness of red and green, with those unaltered coded as black.](jcav07p0711g001){#F1}

![**Quantitative real-time PCR (qPCR) analysis**showing stepwise expression of *CSF2* mRNA associated with significant increase in advanced primary pT status in UBUC.](jcav07p0711g002){#F2}

![**Both CSF2 and pSTAT5 immunostaining** on representative sections of normal urothelium (A & C) and high-grade infiltrating urothelial carcinoma **(B** & **D)**, respectively, exhibits stepwise increased expression. The non-neoplastic urothelium shows very low expression of both CSF2 and pSTAT5 (insets in A & C).](jcav07p0711g003){#F3}

![**Kaplan-Meier plots** revealing both the prognostically significant expression of CSF2 and pSTAT5 in UTUC (A & E, DSS; **B** & **F**, MeFS) and UBUC (**C** & **G**, DSS; **D** & **H**, MeFS)](jcav07p0711g004){#F4}

###### 

Summary of two significantly and differentially expressed genes related to positive regulation of tyrosine phosphorylation of pSTAT5 in the published transcriptome of UBUC (GSE32894).

  Probe          Comparing T2-4 to Ta   Gene Symbol   Biological Process   Molecular Function                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  -------------- ---------------------- ------------- -------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------
  ILMN_1661861   0.4506                 \<0.001       *CSF2*               immune response, myeloid dendritic cell differentiation, positive regulation of DNA replication, positive regulation of cell proliferation, positive regulation of survival gene product expression, positive regulation of tyrosine phosphorylation of Stat5 protein                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           cytokine activity, granulocyte macrophage colony-stimulating factor receptor binding
  ILMN_2056087   0.1919                 0.006         *IGF1*               DNA replication, Ras protein signal transduction, anti-apoptosis, branching morphogenesis of a tube, cell development, cell motion, chondroitin sulfate proteoglycan biosynthetic process, glial cell differentiation, glycolate metabolic process, mammary gland development, multicellular organism growth, muscle hypertrophy, muscle organ development, myoblast differentiation, myoblast proliferation, myotube cell development, negative regulation of smooth muscle cell apoptosis, nervous system development, organ morphogenesis, phosphoinositide 3-kinase cascade, phosphoinositide-mediated signaling, positive regulation of DNA replication, positive regulation of Ras protein signal transduction, positive regulation of epithelial cell proliferation, positive regulation of fibroblast proliferation, positive regulation of gene-specific transcription, positive regulation of glycolysis, positive regulation of granule cell precursor proliferation, positive regulation of insulin-like growth factor receptor signaling pathway, positive regulation of mitosis, positive regulation of smooth muscle cell migration, positive regulation of smooth muscle cell proliferation, positive regulation of transcription from RNA polymerase II promoter, positive regulation of tyrosine phosphorylation of Stat5 protein, regulation of protein metabolic process, regulation of steroid hormone receptor signaling pathway, satellite cell maintenance involved in skeletal muscle regeneration, sensory perception of sound, signal transduction, skeletal system development, water homeostasis   growth factor activity, hormone activity, insulin receptor binding, insulin-like growth factor receptor binding, protein binding

###### 

Association between expression of CSF2 and other important clinicopathological variables in UC.

  Parameter               Category        Upper Urinary Tract Urothelial Carcinoma   Urinary Bladder Urothelial Carcinoma                                       
  ----------------------- --------------- ------------------------------------------ -------------------------------------- ----- ----------- ----- ----- ----- -----------
  Sex                     Male            158                                        87                                     71    0.082       216   112   104   0.339
  Female                  182             83                                         99                                           79          36    43          
  Age (years)             \< 65           138                                        65                                     73    0.377       121   63    58    0.587
  ≥ 65                    202             105                                        97                                           174         85    89          
  Tumor location          Renal pelvis    141                                        80                                     61    0.108       \-    \-    \-    \-
  Ureter                  150             67                                         83                                           \-          \-    \-    \-    
  Renal pelvis & ureter   49              23                                         26                                           \-          \-    \-    \-    
  Multifocality           Single          278                                        142                                    136   0.399       \-    \-    \-    \-
  Multifocal              62              28                                         34                                           \-          \-    \-    \-    
  Primary tumor (T)       Ta              89                                         55                                     34    0.011\*     84    54    30    \<0.001\*
  T1                      92              48                                         44                                           88          52    36          
  T2-T4                   159             67                                         92                                           123         42    81          
  Nodal metastasis        Negative (N0)   312                                        160                                    152   0.115       266   139   127   0.030\*
  Positive (N1-N2)        28              8                                          20                                           29          9     20          
  Histological grade      Low grade       56                                         34                                     22    0.079       56    37    19    0.008\*
  High grade              284             136                                        148                                          239         111   128         
  Vascular invasion       Absent          234                                        123                                    111   0.160       246   136   110   \<0.001\*
  Present                 106             47                                         59                                           49          12    37          
  Perineural invasion     Absent          321                                        167                                    154   0.002\*     275   145   130   0.001\*
  Present                 19              3                                          16                                           20          3     17          
  Mitotic rate/ 10HPFs)   \< 10           173                                        92                                     81    0.233       139   74    65    0.320
  \>= 10                  167             78                                         89                                           156         74    82          
  pSTAT5 expression       Low             170                                        110                                    60    \<0.001\*   148   103   45    \<0.001\*
  High                    170             60                                         110                                          147         44    103         

\* Statistically significant

###### 

Univariate log-rank analysis and multivariate analysis for DSS and MeFS in UTUC.

  Parameter               Category        Case No.   DSS   MeFS                                                                              
  ----------------------- --------------- ---------- ----- ------------ -------------- ---- ----------- ---- ------------ ------------- ---- ---------
  Sex                     Male            158        28    0.8286       \-             \-   \-          32   0.7904       \-            \-   \-
  Female                  182             33               \-           \-             \-   38               \-           \-            \-   
  Age (years)             \< 65           138        26    0.9943       \-             \-   \-          30   0.8470       \-            \-   \-
  ≥ 65                    202             35               \-           \-             \-   40               \-           \-            \-   
  Tumor side              Right           177        34    0.7366       \-             \-   \-          38   0.3074       \-            \-   \-
  Left                    154             26               \-           \-             \-   32               \-           \-            \-   
  Bilateral               9               1                \-           \-             \-   0                \-           \-            \-   
  Tumor location          Renal pelvis    141        24    0.0079\*     1              \-   0.798       31   0.0659       \-            \-   \-
  Ureter                  150             22               0.839        0.451-1.562         25               \-           \-            \-   
  Renal pelvis & ureter   49              15               1.124        0.314-4.024         14               \-           \-            \-   
  Multifocality           Single          273        48    0.0026\*     1              \-   0.003\*     52   0.0127\*     1             \-   0.007\*
  Multifocal              62              18               3.185        1.476-6.875         18               2.162        1.239-3.774        
  Primary tumor (pT)      pTa             89         2     \<0.0001\*   1              \-   0.130       4    \<0.0001\*   1             \-   0.251
  pT1                     92              9                3.349        0.715-15.681        15               2.431        0.760-7.775        
  pT2-T4                  159             50               4.619        1.025-20.810        51               2.855        0.928-8.781        
  Nodal metastasis        Negative (N0)   312        42    \<0.0001\*   1              \-   \<0.001\*   55   \<0.0001\*   1             \-   0.002\*
  Positive (N1-N2)        28              19               5.311        2.849-9.899         15               2.622        1.544-5.348        
  Histological grade      Low grade       56         4     0.0215\*     1              \-   0.006\*     3    0.0027\*     1             \-   0.055
  High grade              284             57               4.055        1.494-11.009        67               2.198        0.983-4.915        
  Vascular invasion       Absent          234        24    \<0.0001\*   1              \-   0.171       26   \<0.0001\*   1             \-   0.003\*
  Present                 106             37               1.515        0.836-2.747         44               2.496        1.367-4.556        
  Perineural invasion     Absent          321        50    \<0.0001\*   1              \-   \<0.001\*   61   \<0.0001\*   1             \-   0.010\*
  Present                 19              11               3.923        1.841-8.354         9                2.755        1.271-5.971        
  Mitotic rate/ 10HPFs    \< 10           173        27    0.167        \-             \-   \-          30   0.0823       \-            \-   \-
  \>= 10                  167             34               \-           \-             \-   40               \-           \-            \-   
  CSF2 expression         Low             170        17    0.0001\*     1              \-   0.045\*     21   0.0001\*     1             \-   0.044\*
  High                    170             44               1.836        1.014-3.325         49               1.756        1.015-3.038        
  pSTAT5 expression       Low             170        22    0.0108\*     1              \-   0.260       24   0.0022\*     1                  0.092
  High                    170             39               1.379        0.788-2.411         46               1.577        0.928-2.681        

\* Statistically significant

###### 

Univariate log-rank analysis and multivariate analysis for DSS and MeFS in UBUC.

  Parameter                                 Category        Case No.   DSS   MeFS                                                                                
  ----------------------------------------- --------------- ---------- ----- ------------ --------------- ---- ----------- ---- ------------ -------------- ---- ---------
  Gender                                    Male            216        41    0.4446       \-              \-   \-          60   0.2720       \-             \-   \-
  Female                                    79              11               \-           \-              \-   16               \-           \-             \-   
  Age (years)                               \< 65           121        17    0.1136       \-              \-   \-          31   0.6875       \-             \-   \-
  ≥ 65                                      174             35               \-           \-              \-   45               \-           \-             \-   
  Primary tumor (pT)                        pTa             84         1     \<0.0001\*   1               \-   \<0.001\*   4    \<0.0001\*   1              \-   0.001\*
  pT1                                       88              9                6.423        0.6959.258           23               5.167        1.513-17.642        
  pT2-T4                                    123             42               24.365       2.829-209.832        49               7.624        2.251-25.831        
  Nodal metastasis                          Negative (N0)   266        41    0.0002\*     1               \-   0.387       61   \<0.0001\*   1              \-   0.028\*
  Positive (N1-N2)                          29              11               1.377        0.680-2.789          15               2.006        1.078-3.732         
  Histological grade                        Low grade       56         2     0.0013\*     1               \-   0.983       5    0.0007\*     1              \-   0.711
  High grade                                239             50               1.134        0.230-5.597          71               1.229        0.414-3.647         
  Vascular invasion                         Absent          246        37    0.0024\*     1               \-   0.125       54   0.0001\*     1              \-   0928
  Present                                   49              15               1.681        0.841-3.356          22               1.029        0.556-1.903         
  Perineural invasion                       Absent          275        44    0.0001\*     1               \-   0.112       66   0.0007\*     1              \-   0.328
  Present                                   20              8                1.959        0.854-4.490          10               1.449        0.689-3.045         
  Mitotic rate (per 10 high power fields)   \< 10           139        12    \<0.0001\*   1               \-   0.018\*     23   \<0.0001\*   1              \-   0.030\*
  \>= 10                                    156             40               2.275        1.152-4.494          53               1.779        1.056-2.997         
  CSF2 expression                           Low             148        9     \<0.0001\*   1               \-   0.003\*     22   0.0002\*     1              \-   0.022\*
  High                                      147             43               3.045        1.445-6.415          54               1.837        1.0903.096          
  pSTAT5 expression                         Low             147        17    0.0086\*     1               \-   0.762       30   0.0307\*     1              \-   0.694
  High                                      148             35               1.101        0.591-2.053          46               0.905        0.552-1.485         

\* Statistically significant

[^1]: Competing Interests: The authors have declared that no competing interest exists.
